Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

被引：29

作者：

Esteve, J ^{[1
]}

Villamor, N ^{[1
]}

Colomer, D ^{[1
]}

Montserrat, E ^{[1
]}

机构：

[1] Hosp Clin Barcelona, Dept Hematol, E-08036 Barcelona, Spain

来源：

BLOOD | 2002年 / 99卷 / 05期

关键词：

D O I：

10.1182/blood.V99.5.1873

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1873 / 1874

页数：2

共 7 条

[1] Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status [J].

Esteve, J ;

Villamor, N ;

Colomer, D ;

Cervantes, F ;

Campo, E ;

Carreras, E ;

Montserrat, E .

LEUKEMIA, 2001, 15 (03) :445-451

[2]

JARQUE I, 1993, BLOOD, V82, P1036

[3] Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease [J].

Mattsson, J ;

Uzunel, M ;

Remberger, M ;

Ljungman, P ;

Kimby, E ;

Ringdén, O ;

Zetterquist, H .

LEUKEMIA, 2000, 14 (02) :247-254

[4]

Mehta J, 1996, BONE MARROW TRANSPL, V17, P371

[5] A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia [J].

Pfitzner, T ;

Engert, A ;

Wittor, H ;

Schinköthe, T ;

Oberhäuser, F ;

Schulz, H ;

Diehl, V ;

Barth, S .

LEUKEMIA, 2000, 14 (04) :754-766

[6] Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy [J].

Rawstron, AC ;

Kennedy, B ;

Evans, PAS ;

Davies, FE ;

Richards, SJ ;

Haynes, AP ;

Russell, NH ;

Hale, G ;

Morgan, GJ ;

Jack, AS ;

Hillmen, P .

BLOOD, 2001, 98 (01) :29-35

[7]

Rondon G, 1996, BONE MARROW TRANSPL, V18, P669

← 1 →